Pulmonary Drug Delivery Systems Market Analysis

  • Report ID: 4410
  • Published Date: Sep 09, 2025
  • Report Format: PDF, PPT

Pulmonary Drug Delivery Systems Market Segmentation:

Application Segment Analysis

The global pulmonary drug delivery systems market is segmented and analyzed for demand and supply by application into asthma, cystic fibrosis, COPD, allergic rhinitis, and others. Out of these segments, the COPD segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the higher prevalence and severity of this disease, backed by the fact that the treatment for COPD is subsidized by government policies and non-governmental organizations that are increasingly providing COPD treatment worldwide. Chronic obstructive pulmonary disease (COPD) can be life-threatening that requires immediate medical attention. For instance, COPD prevalence worldwide was 10% in 2019, accounting for 390 million cases among people over 40 years. Therefore, these factors are anticipated to drive segment growth during the forecast period.

Product Segment Analysis

The global pulmonary drug delivery systems market is also segmented and analyzed for demand and supply by product into metered dose inhalers, dry powder inhalers, nebulizers, and accessories. Amongst these segments, the nebulizers segment is expected to garner a significant share. Nebulizers are highly used for the treatment of asthma and other respiratory diseases. Nebulizers come in two types, ultrasonic and jet nebulizers. Jet nebulizers can compress air and oxygen passing by narrow orifice. Additionally, nebulizers are the traditional method to cure respiratory diseases, hence, people are more inclined to use nebulizers over other methods. Furthermore, high export and import volumes of nebulizers across the globe are also expected to propel the growth of the segment over the forecast period.

Our in-depth analysis of the global market includes the following segments:

                       By Product

  • Metered Dose Inhalers
  • Dry Powder Inhalers
  • Nebulizers
  • Accessories

                        By Application

  • Asthma
  • Cystic Fibrosis
  • COPD
  • Allergic Rhinitis
  • Others

                      By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • E-Commerce

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of pulmonary drug delivery systems is assessed at USD 62.05 Billion.

The global pulmonary drug delivery systems market size was valued at over USD 59.33 Billion in 2025 and is expected to expand at a CAGR of around 5.1%, surpassing USD 97.57 Billion revenue by 2035.

The North America pulmonary drug delivery systems market is predicted to capture 45.2% share by 2035, fueled by rising prevalence of lung diseases and air pollution.

Key players in the market include Novartis AG, Lupin Limited, Briggs Healthcare, Inc., Boehringer Ingelheim International GmbH, Koninklijke Philips N.V., Merck & Co., Inc., 3M Company, AstraZeneca PLC, GSK plc, GF Health Products, Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos